Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2023-03-20

Target enrollment:

Participant gender:

Summary

This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.

Phase:

Phase 1

Details

Lead Sponsor:

Gannex Pharma Co., Ltd.

Collaborator:

Ascletis Pharmaceuticals Co., Ltd.